SMO and skin basal cell carcinoma: Other SMO inhibitors, as LY3039478 (Taledigib), IPI-926 (saridegib), and PF-04449913 (glasdegib), are currently being investigated in clinical trials in advanced solid tumors, including BCC [98,99,100].